BNTC on Nasdaq
Benitec Biopharma Ltd
Logo: benitec.com4
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Silo Pharma, Inc., Oncotelic Therapeutics, Inc. or Incannex Healthcare Inc., or pick any stock.
- TickerBNTC on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersSydney1
- Websitewww.benitec.com
- Incorporated inDE6
- Business address3940 Trust Way, Hayward, Ca 945456
- Filer categoryNon-accelerated filer, Smaller reporting company6
See how the biggest companies compare on our leaderboards
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Research and development | $23.4M | $18.3M |
| General and administrative | $27.8M | $23.4M |
| Total operating expenses | $51.2M | $41.8M |
| Loss from operations | -$51.2M | -$41.8M |
| Foreign currency transaction gain (loss) | $120.0K | -$71.0K |
| Interest income, net | $5.6M | $3.3M |
| Other expense, net | -$43.0K | -$131.0K |
| Gain on extinguishment of liabilities | $0 | $764.0K |
| Total other income, net | $5.6M | $3.8M |
| Unrealized foreign currency translation gain (loss) | -$124.0K | $53.0K |
| Total other comprehensive income (loss) | -$124.0K | $53.0K |
| Total comprehensive loss | -$45.7M | -$37.9M |
| Net loss | -$45.5M | -$37.9M |
| Net loss attributable to common shareholders | -$45.5M | -$37.9M |
| Net loss per share: basic | -$0.98 | -$1.05 |
| Net loss per share: diluted | -$0.98 | -$1.05 |
| Weighted Average Number of Shares Outstanding, Basic | 46.6M shares | 36.2M shares |
| Weighted Average Number of Shares Outstanding, Diluted | 46.6M shares | 36.2M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-11-30 |
|---|---|---|---|
| Cash and cash equivalents | $180.0M | $97.7M | |
| Restricted cash | $114.0K | $113.0K | |
| Trade and other receivables | $4.0K | $33.0K | |
| Prepaid and other assets | $1.6M | $628.0K | |
| Total current assets | $181.7M | $98.5M | |
| Property and equipment, net | $178.0K | $131.0K | |
| Deposits | $55.0K | $55.0K | |
| Prepaid and other assets | $12.0K | $28.0K | |
| Right-of-use assets | $693.0K | $860.0K | |
| Total assets | $182.6M | $99.6M | |
| Trade and other payables | $4.3M | $1.0M | |
| Accrued employee benefits | $553.0K | $426.0K | |
| Lease liabilities, current portion | $496.0K | $354.0K | |
| Total current liabilities | $5.3M | $1.8M | |
| Lease liabilities, less current portion | $266.0K | $495.0K | |
| Total liabilities | $5.6M | $2.3M | |
| Common stock, $0.0001 par value-160,000,000 shares authorized; 34,416,834 and 26,250,469 shares issued and outstanding at June 30, 2026 and June 30, 2025, respectively | $3.0K | $2.0K | |
| Additional paid-in capital | $451.7M | $326.3M | |
| Accumulated deficit | -$273.7M | -$228.2M | |
| Accumulated other comprehensive loss | -$963.0K | -$839.0K | |
| Total stockholders' equity | $177.0M | $97.3M | |
| Total liabilities and stockholders' equity | $182.6M | $99.6M | |
| Common Stock Par Value | $0.00 | $0.00 | |
| Common Stock Shares Authorized | 160.0M shares | 160.0M shares | |
| Common Stock, Shares Issued | 34.4M shares | 26.3M shares | |
| Common Stock, Shares Outstanding | 34.4M shares | 26.3M shares | |
| Preferred Stock, Par Value | $0.00 | $0.00 | $0.00 |
| Preferred Stock, Shares Authorized | 5.0M shares | 5.0M shares | 5.0M shares |
| Preferred Stock, Shares Issued | 0 shares | 0 shares | |
| Preferred Stock, Shares Outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$45.5M | -$37.9M |
| Depreciation and amortization | $58.0K | $66.0K |
| Amortization of right-of-use assets | $423.0K | $330.0K |
| Gain on extinguishment of liabilities | $0 | -$764.0K |
| Share-based compensation expense | $26.4M | $17.4M |
| Trade and other receivables | $30.0K | $197.0K |
| Prepaid and other assets | -$948.0K | -$111.0K |
| Trade and other payables | $3.3M | -$2.4M |
| Accrued employee benefits | $126.0K | -$81.0K |
| Lease liabilities | -$343.0K | -$356.0K |
| Net cash used in operating activities | -$16.5M | -$23.6M |
| Purchase of property and equipment | -$105.0K | -$18.0K |
| Net cash used in investing activities | -$105.0K | -$18.0K |
| Proceeds from the issuance of common stock | $104.5M | $30.5M |
| Proceeds from exercise of pre-funded warrants, Series 2 warrants and common warrants | $748.0K | $42.3M |
| Share and warrant issuance transaction costs | -$6.3M | -$2.3M |
| Net cash provided by financing activities | $99.0M | $70.5M |
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash | -$125.0K | $49.0K |
| Net increase in cash, cash equivalents, and restricted cash | $82.2M | $46.9M |
| Initial measurement of operating lease right-of-use assets and liabilities | $0 | $255.0K |
| Re-measurement of operating lease right-of-use assets and liabilities | $256.0K | $666.0K |
Timeline
- 1997Founded Founded1
Recent filings
- Oct 5, 20268-K
- Sep 30, 20268-K
- Sep 24, 20268-K
- Sep 21, 2026EFFECT
- Sep 14, 20268-K
- Sep 14, 202610-K
- Sep 14, 2026S-3
- Jun 30, 20264
- May 29, 20268-K
- May 28, 20263
- May 28, 20264
- May 14, 20268-K
- May 14, 202610-Q
- Apr 3, 2026UPLOAD
- Mar 20, 202610-K/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- WikipediaBenitec Biopharma
- WikidataQ17001319
- SEC EDGARCIK 1808898
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3WikipediaBenitec Biopharma Ltd on Wikipedia
- 4Company websiteBenitec Biopharma Ltd logo
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14